All results
8 results for yoga intervention women cancer 0
-
IMPACT; Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult GBM
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult…
- Ages
- 18 Years - 80 Years
- Sexes
- All
-
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
NIH AIM 2 - Low Dose Pioglitazone in NASH
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…
- Ages
- 21 Years - 75 Years
- Sexes
- All
-
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…
- Ages
- 12 Years - 99 Years
- Sexes
- All
-
DoD Mastectomy
Breast cancer is the most common type of cancer in women. Removal of the breast, called "mastectomy", is performed either when there is cancer-or an increased…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Addition of Pembrolizumab to Usual Intravesical Gemcitabine for Treatment of BCG-Unresponsive NMIBC
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mix
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia…
- Ages
- 1 Year - 25 Years
- Sexes
- All
-
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is a potential new treatment for people with certain solid tumors. Before ASP1002 is available as a treatment, the researchers need to understand how…
- Ages
- 18 Years - N/A
- Sexes
- All